Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Gemcitabine and Cisplatin in Metastatic TNBC
NCT01939418Phase 2Terminated
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in triple negative breast cancer (TNBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2013; status: terminated.
02
Drugs
everolimus
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01939418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939418.